Home > Insider Trading > Filing (0001562180-16-003674)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	Pharmaceutical Preparations (2834)	272546083

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598426	William Aliski	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-12-05	6,000	$21.00	65,985	No	4	M	Direct
Common Stock	Disposition	2016-12-05	4,000	$77.94	61,985	No	4	S	Direct
Common Stock	Disposition	2016-12-05	2,000	$78.70	59,985	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2016-12-05	6,000	$0.00	6,000	$21.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,500		2024-01-29	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.60 to $78.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $78.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
1/3 of the shares initially subject to the option vested one year from January 30, 2014 and then 1/36 of the shares initially subject to the option began vesting monthly thereafter.